Gland Pharma Limited announced key decisions from its Board Meeting held on June 15, 2026. The Board approved the re-appointment of Mr. Udo Jahannes Vetter as Independent Director for a second five-year term. Additionally, Mr. William Robert Keller was appointed as an Additional Director. The meeting also accepted the resignation of Mr. Satyanarayana Murthy Chavali due to a potential conflict of interest.
Gland Pharma Board Meeting Decisions
On June 15, 2026, the Board of Directors of Gland Pharma Limited convened for a significant meeting where several key resolutions were passed. The board addressed matters concerning director appointments and resignations, adhering to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Re-appointment of Independent Director
The Board approved the re-appointment of Mr. Udo Jahannes Vetter (DIN: 00707474) as an Independent Director of the Company. This re-appointment is for a second term of five consecutive years, effective from July 21, 2026, through to July 20, 2031. Shareholders’ approval for this re-appointment will be sought through postal ballot and e-voting within the stipulated timelines.
Appointment of Additional Director
The Board also approved the appointment of Mr. William Robert Keller (DIN: 11593622) as an Additional Director (Non-Executive – Independent Director) of the Company, effective from June 15, 2026. Mr. Keller, currently an Independent Director at Wuxi Biologics Limited, brings extensive experience to the board. The necessary shareholder approval for this appointment will be obtained via postal ballot and e-voting.
Resignation of Independent Director
Mr. Satyanarayana Murthy Chavali, an Independent Director, has tendered his resignation from the Board. This decision stems from the potential for a conflict of interest that may arise in the future, as the company in which he is a promoter and director is proposing to enter a business segment similar to or overlapping with Gland Pharma’s future business activities. The resignation was effective from the close of business hours on June 15, 2026. The Board expressed its appreciation for Mr. Murthy’s leadership and contribution.
Changes in Subsidiary Board and Committees
Consequent to Mr. C.S.N. Murthy’s resignation, Mr. Essaji Goolam Vahanvati has been appointed as a Director on the Board of Gland Pharma International Pte. Ltd., the Company’s material subsidiary, effective from June 15, 2026. The Board committees have also been realigned to reflect these changes, with specific appointments and reassignments detailed in the enclosed annexures.
Meeting Details
The Board Meeting commenced at 15:00 Hrs. IST and concluded at 15:50 Hrs. IST on June 15, 2026.
Source: BSE
